PART I . Our Company MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2 -deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia. In December 2022, reg...
Q2 FY2026 — expected 2026-09-26
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001493152-26-012088 | EDGAR | 113K words |
| 2025-03-21 | 2024-12-31 | 0000950170-25-043190 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034764 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009766 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001493152-25-021272 | EDGAR | 32K words |
| 2025-08-11 | 2025-06-30 | 0001641172-25-022899 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068005 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125474 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094747 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059550 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059778 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039399 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018480 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023956 | EDGAR | — |
| 2022-08-22 | 2022-06-30 | 0000950170-22-017637 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001493152-26-014924 | EDGAR | 1K words |
| 2026-03-31 | 0001493152-26-013879 | EDGAR | — |
| 2026-03-27 | 0001493152-26-013088 | EDGAR | — |
| 2026-03-04 | 0001493152-26-008897 | EDGAR | — |
| 2026-02-24 | 0001493152-26-007831 | EDGAR | — |
| 2026-01-20 | 0001493152-26-002883 | EDGAR | — |
| 2026-01-13 | 0001493152-26-002085 | EDGAR | — |
| 2025-12-17 | 0001493152-25-028041 | EDGAR | — |
| 2025-12-11 | 0001493152-25-027244 | EDGAR | — |
| 2025-12-10 | 0001493152-25-027072 | EDGAR | — |
147 total filings indexed. 122 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001878313 |
| Ticker | MAIA |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.maiabiotech.com |
| Listed | 2022-07-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report